Phase 2, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety and antiviral activity of JNJ-63623872 in combination with oseltamivir in adolescent, adult and elderly patients hospitalized for influenza A infection.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: JANSSEN-CILAG INTERNATIONAL NV
- Phase: II
- Execution start: 07/11/2016
- End of execution: 30/04/2018
- PI: JUAN PASQUAU LIAÑO